The company, headed by president and CEO Flemming Ørnskov (ex-Shire), has 33 sites in 100 countries[4] with a worldwide network of distributors and employs more than 4,600 people.

[4] It diversified into aesthetic medicine products with the botulinum toxin Azzalure, a field in which it strengthened in 2010 with the acquisition of the Swedish medical-device company Q-Med.

[11] In November 2021, Galderma bought California-based Alastin, a firm specialising in specialist skincare products, for an undisclosed price.

[5][12] In June 2022, Galderma announced positive results in two Phase III trials for liquid botulinum toxin A, showing RelabotulinumtoxinA was well tolerated.

[13] Also in June 2022, Galderma announced positive data from Phase III trial, showing efficacy and safety of nemolizumab in patients with prurigo nodularis.

[citation needed] In 2007, Galderma and Ipsen signed a licensing agreement for the distribution of the botulinum toxin Dysport, known as Azzalure in the European Union.

[21] The main brands are Restylane, Azzalure, Dysport, Alluzience, Sculptra and Relfydess (relabotulinumtoxinA), which received a positive decision for use in Australia[22] and in the European Union in July 2024.

[citation needed] The main brands are Aklief, Benzac, Cetaphil, Epiduo, Epiduo Forte, Twyneo, Epsolay, Loceryl, Differin, Soolantra, Mirvaso, Oracea, Metvix and Nemluvio which received US Food and drug Administration approval for adult patients living with prurigo nodularis in August 2024[24] and for patients with atopic dermatitis in December 2024.